Keytruda (pembrolizumab)

pCPA File Number: 22011
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
PC0279
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable